Skip to main content

Table 2 Subgourp analyses of EFS on TET2 mutation

From: The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis

Variables Number of studies, heterogeneity I2%, p Pooled HRs(95% CI), P value Interaction(p)
Year 2016 1 3.430[1.479–7.955], P = 0.004 0.096
2015 3(74.8), P = 0.019 1.320[0.911–1.913], P = 0.142
2014 1 0.800[0.327–1.955], P = 0.624
2012 2(1.7), P = 0.313 1.613[1.217–2.138], P = 0.001
2011 1 1.320[0.982–1.774], P = 0.066
2010 1 3.970[1.140–13.826], P = 0.030
Data type Multivariate 3(76.4), P = 0.014 1.284[0.891–1.850], P = 0.181 0.110
Calculated from K-M curves 5(26.2), P = 0.247 1.473[1.209–1.794], P < 0.001
univariate 1 3.430[1.479–7.955], P = 0.004
Region America 2(83.0), P = 0.015 1.479[1.117–1.959], P = 0.006 0.413
Europe 4(44.1), P = 0.147 1.580[1.215–2.055], P = 0.001
Asia 2(76.4), P = 0.040 1.934[1.020–3.667], P = 0.043
other 1 1.076[0.688–1.682], P = 0.748
Cohort AML 2(79.4), P = 0.028 1.669[1.189–2.344], P = 0.003 0.444
CN-AML 5(47.5), P = 0.106 1.377[1.120–1.692], P = 0.002
Others 2(76.4), P = 0.040 1.934[1.020–3.667], P = 0.043
Detection methods Direct sequencing 6(13.1), P = 0.331 1.283[1.058–1.556], P = 0.011 0.002
Next-generation sequencing 3(38.3), P = 0.198 2.418[1.691–3.459], P < 0.001
  1. Abbreviations: HRs hazard ratios, CN-AML cytogenetically normal acute myeloid leukemia